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Introduction: Platelet mitochondrial respiratory chain enzymes (that produce energy) are variably inhibited during
human sepsis. Whether these changes occur even during other acute critical illness or are associated with impaired
platelet aggregation and secretion (that consume energy) is not known. The aims of this study were firstly to compare
platelet mitochondrial respiratory chain enzymes activity between patients with sepsis and those with cardiogenic
shock, and secondly to study the relationship between platelet mitochondrial respiratory chain enzymes activity and
platelet responsiveness to (exogenous) agonists in patients with sepsis.
Methods: This was a prospective, observational, case–control study. Platelets were isolated from venous blood of 16
patients with severe sepsis or septic shock (free from antiplatelet drugs) and 16 others with cardiogenic shock, within
48 hours from admission to Intensive Care. Platelet mitochondrial respiratory chain enzymes activity was measured
with spectrophotometry and expressed relative to citrate synthase activity, a marker of mitochondrial density. Platelet
aggregation and secretion in response to adenosine di-phosphate (ADP), collagen, U46619 and thrombin receptor
activating peptide were measured with lumiaggregometry only in patients with sepsis. In total, 16 healthy volunteers
acted as controls for both spectrophotometry and lumiaggregometry.
Results: Platelets of patients with sepsis or cardiogenic shock similarly had lower mitochondrial nicotinamide adenine
dinucleotide dehydrogenase (NADH) (P < 0.001), complex I (P = 0.006), complex I and III (P < 0.001) and complex IV
(P < 0.001) activity than those of controls. Platelets of patients with sepsis were generally hypo-responsive to exogenous
agonists, both in terms of maximal aggregation (P < 0.001) and secretion (P < 0.05). Lower mitochondrial NADH
(R2 0.36; P < 0.001), complex I (R2 0.38; P < 0.001), complex I and III (R2 0.27; P = 0.002) and complex IV (R2 0.43; P < 0.001)
activity was associated with lower first wave of aggregation with ADP.
Conclusions: Several platelet mitochondrial respiratory chain enzymes are similarly inhibited during human sepsis
and cardiogenic shock. In patients with sepsis, mitochondrial dysfunction is associated with general platelet
hypo-responsiveness to exogenous agonists.
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The pathogenesis of multiple organ failure during sepsis
remains unclear. According to one hypothesis, overt
systemic inflammation in response to infection inhibits
mitochondria (the ‘powerhouse of the cell’ [1]). As a conse-
quence, organs become unable to produce enough energy
to maintain their normal activities: the organs enter into a
hypometabolic state and lose their functions [2,3].
Testing this hypothesis in humans is problematic
because of difficult access to vital organs. Circulating
platelets are rich in mitochondria and can be obtained
easily even from critically ill patients. Platelet mitochon-
drial function can be assessed with different techniques.
For instance, spectrophotometry can measure the activity
of enzymes that form the respiratory chain and are
devoted to energy production [4] in platelets just as in
other tissues [5,6]. Using spectrophotometry, we [7] and
other authors [8] have noted that these mitochondrial
enzymes are variably inhibited in platelets of septic
patients. However, no one has ever clarified whether these
changes are specific to sepsis (in order to better define
underlying mechanisms) or whether they are related to
changes in platelet aggregation and secretion in response
to agonists (to verify the association between mitochon-
drial inhibition and cellular loss of function).
In resting platelets, mitochondrial respiration normally
accounts for three-quarters of energy production, with
glycolysis providing the rest [9]. Metabolic ATP and
ADP are in the cytoplasm with a ratio of 7 to 10 and
represent one-third of total intraplatelet adenine nucleo-
tides. Nonmetabolic ATP and ADP are segregated into
dense (δ) granules with a ratio of around 1 and represent
the other two-thirds of total adenine nucleotides; they
are secreted upon cellular stimulation and are essential
for the late phase (or second wave) of aggregation [10].
Therefore, most of the total intraplatelet ATP is in the
cytoplasm (metabolic pool) whereas most of the total
ADP is in δ-granules (storage pool). Serotonin is another
constituent of δ-granules. Following platelet activation,
mitochondrial respiration and glycolysis accelerate to
produce extra metabolic ATP to sustain shape change,
aggregation and secretion [11,12]. This incremental energy
consumption is one major determinant of platelet
function [12]. When mitochondria are inhibited,
glycolysis alone can produce enough energy for resting
cells, but not for activated cells. This is the reason why
mitochondrial inhibitors diminish platelet inducible (and
energy demanding [13]) responses [14-18].
The aims of this study were to compare platelet
mitochondrial respiratory chain enzyme activity between
patients with sepsis and those with cardiogenic shock
(when the trigger for inflammation is hypoperfusion and
not infection) and to study the relationship between mito-
chondrial respiratory chain enzyme activity and plateletresponsiveness to (exogenous) agonists in patients with
sepsis.
Materials and methods
This study was approved by the Ethics Committee of the
Fondazione IRCCS Ca’ Granda – Ospedale Maggiore
Policlinico, Milan, Italy and was registered on 8 October
2007 at ClinicalTrials.gov (NCT00541827). Written con-
sent was obtained from patients (when they returned
conscious) and healthy volunteers.
We enrolled 16 adults with severe sepsis or septic
shock [19] and 16 others with cardiogenic shock [20]
within 48 hours from admission to intensive care. Sixteen
healthy volunteers matched for sex and age acted as
controls. Exclusion criteria were platelet transfusion
within the last 15 days, severe thrombocytopenia
(<20 × 103 platelets/mm3) or anaemia (<8 g/dl) and
known mitochondrial disease. In addition, patients
with sepsis and controls were excluded if they had received
anti-serotoninergic or anti-platelet drugs within the last
15 days. This criterion did not apply to patients with
cardiogenic shock, who were expected to have received
anti-platelet drugs (for acute coronary syndrome) by the
time they were admitted to intensive care. We therefore
decided a priori to study mitochondrial respiratory chain
enzyme activity but not platelet function in this group of
patients.
Platelet mitochondrial biochemistry
Ethylene diamine tetra-acetic acid-anticoagulated venous
blood was sedimented for 45 minutes at 4°C. The top
three-quarters of platelet-rich plasma were centrifuged
at 5,000 × g for 10 minutes. The pellet was washed with
distilled water, centrifuged at 14,500 × g for 10 minutes,
washed again with phosphate-buffered saline and finally
stored at −80°C. At the time of analysis, the platelet pellet
was diluted in buffer (KCl 120 mM, 4-(2-hydroxyethyl)-1-
piperazine ethanesulfonic acid 20 mM, MgCl2 5 mM and
ethylene glycol tetra-acetic acid 1 mM; pH 7.2, 300 to
400 μl), sonicated (two cycles at 60 W for 10 seconds) and
centrifuged (750 × g for 10 minutes) while kept at 4°C.
Supernatant was then analysed using spectrophotometry
at 30°C. We measured the activity of nicotinamide
adenine dinucleotide dehydrogenase (NADH), NADH–
ubiquinone 1 reductase (complex I), NADH–cytochrome c
reductase (complex I + III), succinate dehydrogenase,
succinate dehydrogenase–cytochrome c reductase (com-
plex II + III) and cytochrome c oxidase (complex IV), the
main components of the mitochondrial respiratory chain
[4], and expressed it relative to citrate synthase activity,
a marker of mitochondrial density [5-7]. Proteins were
measured with Lowry’s method. Data referred to seven
patients with sepsis herein reported have also been
presented in another publication [7].
Table 1 Main characteristics of subjects enrolled in the study
Healthy controls Sepsis Cardiogenic shock P value
n 16 16 16
Sex (male/female) 7/9 7/9 9/7 0.716
Age (years) 61 ± 11 62 ± 16 66 ± 17 0.306
Diabetes 1 2 6 0.110
Obesity 1 4 5 0.248
Smoking history 3 3 3 1.000
SAPS II – 42 ± 12 75 ± 17 <0.001
SOFA score – 9 (6 to 11) 12 (11 to 14) <0.001
Respiration – 3 (2 to 4) 3 (2 to 4) 0.984
Coagulation – 1 (0 to 2) 0 (0 to 0) 0.007
Liver – 0 (0 to 1) 0 (0 to 1) 0.748
Cardiovascular – 4 (3 to 4) 4 (3 to 4) 0.746
Central nervous system – 0 (0 to 0) 4 (3 to 4) <0.001
Renal – 0 (0 to 1) 1 (1 to 2) 0.022
Platelet count (× 103/mm3) 229 (191 to 268) 140* (93 to 183) 180 (153 to 221) <0.001
Central (or mixed) venous oxygen saturation (%) – 74 ± 9 62 ± 14 0.015
Blood lactate (mmol/l) – 2 ± 2 10 ± 5 <0.001
Antibiotic(s) – 16 6 <0.001
Sedative(s) intravenously – 13 12 1.000
Catecholamine(s) – 13 16 0.226
Mechanical ventilation – 15 15 1.000
Renal replacement therapy – 0 1 1.000
Intra-aortic balloon pump – 0 2 0.484
Days from hospital to ICU admission – 0 (0 to 1) 1 (0 to 8) 0.074
Hours from ICU admission to study enrolment – 22 ± 13 9 ± 6 <0.001
Length of stay in ICU (days) – 16 (6 to 24) 1 (1 to 2) <0.001
Deaths in ICU – 5 10 0.156
Data reported as number, mean ± standard deviation or median (interquartile range). Patients with sepsis or cardiogenic shock entered the study within 48 hours from
admission to intensive care (ICU). Obesity was defined as body mass index ≥30 kg/m2. Smoking history was not known for two patients with sepsis and two patients
with cardiogenic shock. Simplified Acute Physiology Score (SAPS) II and Sequential Organ Failure Assessment (SOFA) scores refer to the first day in the ICU. Central
(n = 16) or mixed (n = 12) venous oxymetry (four missing values) and blood lactate levels (one missing value) are the worst values recorded from ICU admission to study
enrolment. Use of artificial organ support refers to this same period of time. P values refer to Student’s t test or the Wilcoxon rank-sum test, one-way analysis of variance
(ANOVA) or one-way ANOVA on ranks (*P <0.05 vs. healthy controls on post hoc all-pairwise multiple comparisons (Tukey or Dunn’s test)), chi-square test or Fisher’s exact
test. In the case of two row × three column contingency tables, the Freeman–Halton extension of Fisher’s exact test was used as appropriate.
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Platelet aggregation and secretion were recorded on a
Chrono-Log lumiaggregometer (Mascia Brunelli, Milan,
Italy). Briefly, 3.8% citrate-anticoagulated venous blood
was centrifuged (1900 × g for 15 minutes) to obtain
platelet-rich plasma. After separation of platelet-rich
plasma, tubes were centrifuged again (1,100 × g for
15 minutes) to obtain platelet-poor plasma. Platelet-rich
plasma (450 μl) was mixed with luciferase reagent
(50 μl) and stirred at 1,000 rpm at 37°C. After 30 seconds,
one of the following agonists that activate different signal
transduction pathways was added (final concentration):
ADP (Sigma Aldrich, St. Louis, MO, USA) 4 μmol/l,collagen (Mascia Brunelli) 2 μg/ml, thromboxane A2
analogue U46619 (Sigma Aldrich) 0.5 μmol/l, and
thrombin receptor activating peptide (Sigma Aldrich)
10 μmol/l. At this dose, ADP elicits a biphasic platelet
response: the first wave of aggregation in response to
exogenous ADP is followed by δ-granule secretion and
the second wave of aggregation in response to released
endogenous adenine nucleotides. By contrast, with other
agonists, aggregation and secretion occur at the same
time, so that the first wave cannot be distinguished from
the second wave of aggregation [21]. First wave (with ADP)
and maximal (over 3 minutes; with all agonists) aggregation
was measured as the decrease in optical density of
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(lowest optical density) as the reference (100% aggre-
gation). Platelet secretion was assessed as the release
of ATP.
Platelet nucleotides
Total ATP and ADP contents were measured with a
LKB 1250 luminometer (Bio-Orbit Oy, Turku, Finland)
using the firefly luciferin–luciferase method (Promega
Corporation, Madison WI, USA). Platelet serotonin content
was measured with the o-phthaldialdehyde system [22].
Plasma interleukin-6
Interleukin-6 was measured in duplicate with enzyme-linked
immunosorbent assays (RayBiotech, Norcross, GA, USA).
Statistical analysis
Data are reported as mean (± standard deviation) or
median (interquartile range). Groups were compared0
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Figure 1 Platelet mitochondrial biochemistry during sepsis or cardioge
healthy volunteers (white bars) and patients with sepsis (grey bars) or cardiog
care). Nicotinamide adenine dinucleotide dehydrogenase (NADH) (A), comple
(D), complex II + III (CII + III) (E), and complex IV (CIV) (F) activity is expressed r
P values refer to one-way analysis of variance (ANOVA) or one-way ANOVA on
comparisons (Tukey or Dunn’s test)). CS activity was 68 ± 8 nmol/minute/mg
patients with sepsis and 59 ± 9 nmol/minute/mg proteins in those with cardio
complex I + III, NADH–cytochrome c reductase; complex II + III, succinate dehydusing Student’s t test or the Wilcoxon rank-sum test,
one-way analysis of variance or one-way analysis of vari-
ance on ranks. Proportions were compared with the chi-
square test or Fisher’s exact test. The strength of association
between variables was measured with linear regression
analysis or Spearman’s rank correlation. P <0.05 indicated
statistical significance (SigmaPlot; Jandel Scientific Software,
San Jose, CA, USA).
Results
The main characteristics of subjects enrolled in the
study are presented in Table 1. Patients with severe
sepsis (n = 3) or septic shock (n = 13) had pulmonary
(n = 9), abdominal (n = 6) or skin (n = 1) infection.
Those with cardiogenic shock had acute myocardial
infarction (n = 10), pulmonary embolism (n = 2), malignant
arrhythmia (n = 2), pericardial tamponade (n = 1) or
prosthetic mitral valve failure (n = 1) eventually complicated
by transient cardiac arrest (n = 10).=0.006
* *
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nic shock. Activity of platelet respiratory chain enzymes was measured in
enic shock (black bars) (within 48 hours from admission to intensive
x I (CI) (B), complex I + III (CI + III) (C), succinate dehydrogenase (SDH)
elative to citrate synthase (CS) activity, a marker of mitochondrial density.
ranks (*P <0.05 vs. healthy volunteers on post hoc all-pairwise multiple
proteins in healthy volunteers, 67 ± 12 nmol/minute/mg proteins in
genic shock (*) (P= 0.026). Complex I, NADH–ubiquinone 1 reductase;
rogenase–cytochrome c reductase; complex IV, cytochrome c oxidase.
Table 2 Platelet response to exogenous agonists during
sepsis
Healthy
controls
Sepsis P value
n 16 16
Maximal aggregation (%)
With ADP (4 μmol/l) 65 ± 18 30 ± 14 <0.001
With collagen (2 μg/ml) 80 ± 9 36 ± 17 <0.001
With U46619 (0.5 μmol/l) 75 ± 19 31 ± 18 <0.001
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glycopeptides, broad-spectrum penicillins and/or quin-
olones, benzodiazepines and opioids, norepinephrine
and/or dopamine. Those with cardiogenic shock were
occasionally treated with clindamycin or broad-spectrum
penicillin (in case of aspiration) and always received
benzodiazepines or propofol, opioids and catecholamine(s)
(mainly dopamine and/or epinephrine). Thirteen pa-
tients with cardiogenic shock received salicylic acid or
its derivatives.With thrombin receptor activating
peptide (10 μmol/l)
72 ± 27 21 ± 17 <0.001
First wave of aggregation (%)
With ADP (4 μmol/l) 53 ± 13 26 ± 10 <0.001
Secretion (nmol ATP/108 platelets)
With ADP (4 μmol/l) 0.20 ± 0.18 0.07 ± 0.10 0.041
With collagen (2 μg/ml) 0.67 ± 0.23 0.35 ± 0.37 0.002
With U46619 (0.5 μmol/l) 0.28 ± 0.13 0.12 ± 0.13 0.003
With thrombin receptor activating
peptide (10 μmol/l)
0.45 ± 0.26 0.13 ± 0.21 <0.001
Data reported as mean ± standard deviation. Platelet maximal aggregation and
secretion (in response to ADP, collagen, thromboxane A2 analogue U46619
and thrombin receptor activating peptide) and first wave of aggregationPlatelet mitochondrial biochemistry
Platelets of patients with sepsis or cardiogenic shock
similarly had lower NADH (20 to 25% reduction),
complex I (30% reduction), complex I and III (30 to
35% reduction) and complex IV (60 to 65% reduction)
activity than those of healthy volunteers. Findings were
similar in patients with cardiogenic shock treated with or
without salicylic acid or its derivatives (P ≥0.414 for the
activity of all respiratory chain enzymes). Platelets of
patients with sepsis also had lower succinate dehydrogenase
activity (20% reduction) than those of controls (Figure 1).(in response to ADP) were measured in healthy volunteers and patients with
sepsis (within 48 hours from admission to intensive care). Aggregation is
expressed as a percentage, where optical density of unstimulated platelet-rich
plasma represents 0% and that of platelet-poor plasma is 100%. Secretion was
measured as ATP released in the extracellular space (nmol/108 platelets). A
curve obtained by adding a fixed dose of ATP to platelet-poor plasma was
used as standard. Please note that the platelet count in platelet-rich plasma of
patients was above 100 × 103 platelets/mm3 in all but two cases. Blood fibrinogen
levels in patients with sepsis were 522 ± 202 mg/ml (internal reference values:
200 to 400 mg/ml). P values refer to Student’s t test or the Wilcoxon
rank-sum test.Platelet aggregation and secretion
As specified above, platelet function was not assessed in
patients with cardiogenic shock (de facto, only one of
these patients had not received antiplatelet drugs by the
time of enrolment).
In patients with sepsis, the platelet first wave of
aggregation (in response to ADP), maximal aggregation
and secretion of ATP (in response to ADP, collagen,
U46619 and thrombin receptor activating peptide) were
significantly lower than those of controls (Table 2). The
first wave of aggregation generally correlated with the
activity of several platelet mitochondrial respiratory chain
enzymes (Figure 2).Platelet nucleotides
Platelets of patients with sepsis had a lower level of total
ADP (1.4 ± 1.0 vs. 2.6 ± 0.7 nmol/108 platelets; P <0.001),
a similar level of total ATP (6.0 ± 2.0 vs. 5.9 ± 1.6 nmol/108
platelets; P = 0.910) and a higher ATP-to-ADP ratio
(6.8 ± 5.3 vs. 2.3 ± 0.5; P < 0.001) than those of healthy
volunteers. They also contained less serotonin than those
of controls (0.29 ± 0.20 vs. 0.48 ± 0.15 nmol/108 platelets;
P = 0.006).Plasma interleukin-6
Interleukin-6 was higher in patients with sepsis (187 (86
to 615) pg/ml; n = 15; P <0.05) or cardiogenic shock
(387 (43 to 626) pg/ml; n = 15; P <0.05) than in controls
(4 (1 to 15) pg/ml; n = 10).Discussion
This study demonstrates that platelet mitochondrial
respiratory chain enzymes are similarly inhibited in
patients with sepsis or cardiogenic shock and that these
changes, during sepsis, are associated with general platelet
hyporesponsiveness.
Platelet mitochondrial dysfunction is not specific to
sepsis. Mitochondrial changes occurring in blood cells
during severe infection are commonly attributed to
circulating factors [23-26], possibly including inflammatory
mediators and drugs. However, systemic inflammation can
also develop in response to sterile insults [27,28] and high
levels of cytokines can be found in blood even after
cardiac failure [29], as confirmed by our own data on
interleukin-6. Patients with cardiogenic shock as well
as those with sepsis commonly received antibiotics,
sedatives or catecholamines that are potentially toxic
for the mitochondrion [30,31]. Accordingly, plasma of
patients resuscitated from cardiac arrest can cause
mitochondrial dysfunction in vitro [32]. These results,
however, do not exclude a major role for infection
(compared with hypoperfusion) in the development of
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Figure 2 Relationship between platelet mitochondrial biochemistry and the first wave of aggregation. Activity of platelet respiratory
chain enzymes and the first wave of aggregation with ADP (4 μmol/l) were measured in healthy volunteers (white dots) and in patients with
sepsis (grey dots) (within 48 hours from admission to intensive care). Nicotinamide adenine dinucleotide dehydrogenase (NADH) (A), complex
I (CI) (B), complex I + III (CI + III) (C), succinate dehydrogenase (SDH) (D), complex II + III (CII + III) (E), and complex IV (CIV) (F) activity is expressed
relative to citrate synthase (CS) activity, a marker of mitochondrial density. Aggregation was expressed as a percentage, where optical density of
unstimulated platelet-rich plasma represents 0% and that of platelet-poor plasma is 100%. Strength of association between (normally distributed)
variables was assessed with linear regression analysis and expressed as R2. CS activity (expressed as nmol/minute/mg proteins) was not associated
with the first wave of aggregation with ADP (R2 = 0.00; P = 0.703). Complex I, NADH–ubiquinone 1 reductase; complex I + III, NADH–cytochrome c
reductase; complex II + III, succinate dehydrogenase–cytochrome c reductase; complex IV, cytochrome c oxidase.
Protti et al. Critical Care  (2015) 19:39 Page 6 of 8mitochondrial dysfunction. In fact, respiratory chain
enzymes were always similarly inhibited although the
severity of disease (Table 1) and inflammatory response
(circulating interleukin-6 levels) were apparently lower
during sepsis than during cardiogenic shock.
Patients with cardiogenic shock, but not those with
sepsis (see inclusion criteria), were almost always treated
with salicylic acid or its derivatives. According to some
authors, these compounds may directly interfere with
(platelet) mitochondrial function, mainly acting as
uncoupling agents [33]. However, in our study popu-
lation, severe platelet mitochondrial inhibition (ratherthan uncoupling) was equally observed in subjects treated
with or without salicylic acid or its derivatives. Preliminary
experiments in our laboratory confirm that complex IV
activity (that was largely depressed in patients with cardio-
genic shock) remains normal in healthy volunteers treated
with aspirin (100 mg/day) for 3 days. Based on these
findings, salicylic acid and its derivatives probably had
only a minor (if any) role in the development of platelet
mitochondrial dysfunction during cardiogenic shock.
Along with signs of mitochondrial dysfunction, platelets
of patients with sepsis were hyporesponsive to several
agonists (as already shown by other authors [34-37]), had
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(main granular components) and had an abnormally high
ATP-to-ADP ratio (that approximated cytoplasmic values).
Total ATP levels that mainly depend on the cytoplasmic
pool were grossly preserved. Overall, these changes suggest
that secretion had already occurred in vivo leaving platelets
functionally exhausted, with empty δ-granules, unable to
further respond to agonists (acquired δ storage pool
disease) [38,39]. Maximal aggregation diminished in line
with secretion and granular content, as it does during
inherited defects of δ-granules [40,41]. This model,
however, does not account for observed inhibition of the
first wave of aggregation in patients with sepsis. In fact, the
first wave of aggregation precedes secretion and is usually
normal even in patients with δ storage pool disease [40,41].
Other mechanisms should then be considered, probably in-
cluding incapacity of platelets to accelerate their energy
turnover because of inhibition of key mitochondrial en-
zymes [42]. Sodium azide, a well-known blocker of mito-
chondrial respiration, similarly interferes with first wave
aggregation induced by ADP in human platelets [43].
Platelet hyporesponsiveness during sepsis may thus
represent, at least in part, an adaptive response to
acquired platelet mitochondrial dysfunction, with the aim
of preserving a physiological balance between energy
demand and provision. Large inhibition of complex IV
probably has a crucial role in this sequence of events, both
limiting cellular respiration and triggering a decrease in
ATP consumption [44].
Some limitations of our study deserve comment. The
sample size was small. Enrolment of patients with sepsis
was particularly difficult due to common use of nonsteroidal
anti-inflammatory drugs (exclusion criteria). Changes occur-
ring in platelets may not reflect those occurring in other
tissues or organs [7]. In addition, spectrophotometry and
lumiaggregometry evaluate ex vivo properties of circulating
platelets. Therefore, they may only partly describe changes
that occur in vivo in platelets eventually entrapped in the
microcirculation. Other aspects of platelet mitochondrial
physiology, such as oxygen consumption or membrane
potential, were not investigated. Platelet mitochondrial
density was evaluated in terms of citrate synthase activity
(normal even in critically ill patients) and not with more
sophisticated techniques, including electron microscopy.
Some authors have noted that platelet citrate synthase activ-
ity relates to other markers of mitochondrial content, such
as mitochondrial DNA, and remains normal during human
sepsis [26]. However, one recent study has demonstrated
that activated platelets release some of their mitochondria
in the extracellular milieu with electron microscopy [45].
Platelet citrate synthase activity may thus be normal in face
of some change in mitochondrial density. Loss of organelles
is expected to result in a parallel decrease in the activity of
all mitochondrial enzymes. By contrast, we have noted aselective, large inhibition of some enzymes but not of others
in critically ill patients, as if platelet mitochondria had a
defect in their activity and not just in their density. Finally,
whether mitochondrial dysfunction was responsible for, and
not only associated with, platelet hyporesponsiveness
remains unclear. For all these reasons, our results should
be interpreted with caution.
Conclusions
Several platelet mitochondrial respiratory chain enzymes
are inhibited during human sepsis or cardiogenic shock.
In patients with sepsis, these mitochondrial changes are
related to general platelet hyporesponsiveness to exogenous
stimulation.
Key messages
 Platelet mitochondrial respiratory chain enzymes are
similarly inhibited in patients with sepsis or
cardiogenic shock.
 In patients with sepsis, platelet mitochondrial
changes are related to general platelet
hyporesponsiveness to exogenous agonists.
 In patients with sepsis, circulating platelets also
suffer from acquired δ storage pool disease.
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